CPT1A and metabolic dysfunction-associated steatotic liver disease: To further confirm that a low‐dose of α‐Toc attenuates the development of NAFLD through the CPT‐1 pathway, an additional experiment exploring the effect of CPT‐1 inhibition was performed.